Autoimmune inflammatory disorders

Our ambition

Our ambition is to develop novel immunotherapies that will significantly improve the lives of people with autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, lupus and inflammatory bowel disease. Novo Nordisk has established a state-of-the-art inflammation research site in Seattle, and we have a number of innovative monoclonal antibody projects in clinical development within autoimmune and inflammatory diseases.

Our partnering focus

Novo Nordisk is committed to building a presence in treating autoimmune and chronic inflammatory diseases.

We welcome first-in-class protein and peptide opportunities from research to clinical stage and focus on the following targets:

  • Molecules on the surface of cells involved in immune regulation
  • Cytokines

Read more about Biopharmaceuticals Research Unit

Contact us

For further information please contact Biopharmaceuticals Innovation Sourcing


  •  

Download partnering for innovation brochure

  •  
  •  

Where to meet us

We are attending events all over the world to meet with new potential partners.

Event calendar

  •  
  •  

R&D pipeline

Read more about our inflammation pipeline.

 

  •